About Corvus Pharmaceuticals, Inc.
https://www.corvuspharma.comCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.
CEO
Richard A. Miller
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 78
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:7.17M
Value:$48.87M
POINT72 ASSET MANAGEMENT, L.P.
Shares:6.45M
Value:$44.02M
BLACKROCK, INC.
Shares:4.71M
Value:$32.13M
Summary
Showing Top 3 of 124
About Corvus Pharmaceuticals, Inc.
https://www.corvuspharma.comCorvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.57M ▲ | $-10.16M ▼ | 0% | $-0.12 ▼ | $-10.13M ▲ |
| Q2-2025 | $0 | $10.26M ▲ | $-8M ▼ | 0% | $-0.1 ▼ | $-10.23M ▼ |
| Q1-2025 | $0 | $9.92M ▲ | $15.19M ▲ | 0% | $0.21 ▲ | $-9.9M ▼ |
| Q4-2024 | $0 | $8.11M ▲ | $-12.11M ▲ | 0% | $-0.18 ▲ | $-8.09M ▼ |
| Q3-2024 | $0 | $7.25M | $-40.22M | 0% | $-0.6 | $-7.23M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $65.69M ▼ | $80.47M ▼ | $8.71M ▼ | $71.77M ▼ |
| Q2-2025 | $74.41M ▲ | $89.46M ▲ | $9.23M ▼ | $80.23M ▲ |
| Q1-2025 | $44.21M ▼ | $59.44M ▼ | $10.11M ▼ | $49.33M ▲ |
| Q4-2024 | $51.96M ▲ | $68.91M ▲ | $36.34M ▼ | $32.57M ▲ |
| Q3-2024 | $41.65M | $58.81M | $46.41M | $12.41M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-10.16M ▼ | $-9.57M ▼ | $-2.62M ▲ | $360K ▼ | $-11.82M ▼ | $-9.57M ▼ |
| Q2-2025 | $-8M ▼ | $-5.78M ▲ | $-20.3M ▼ | $35.77M ▲ | $9.69M ▲ | $-5.89M ▲ |
| Q1-2025 | $15.19M ▲ | $-8.26M ▲ | $4.24M ▲ | $279K ▼ | $-3.74M ▼ | $-8.3M ▲ |
| Q4-2024 | $-12.11M ▲ | $-8.46M ▼ | $-6.08M ▼ | $18.61M ▲ | $4.06M ▲ | $-8.46M ▼ |
| Q3-2024 | $-40.22M | $-6.32M | $-3.89M | $50K | $-10.16M | $-6.32M |
CEO
Richard A. Miller
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 78
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:7.17M
Value:$48.87M
POINT72 ASSET MANAGEMENT, L.P.
Shares:6.45M
Value:$44.02M
BLACKROCK, INC.
Shares:4.71M
Value:$32.13M
Summary
Showing Top 3 of 124